Selvita S.A. is a drug discovery company, developing breakthrough therapies in the area of oncology. The company’s most advanced R&D program is SEL24, a Phase I dual PIM/FLT3 kinase inhibitor. Other projects include SEL120, a first-in-class small molecule inhibitor of CDK8 in preclinical studies, as well as several drug discovery platforms in immunooncology, immunometabolism and cancer metabolism as well as epigenetics performed independently or in collaboration with global pharma and biotech companies.
Selvita also offers a wide range of integrated drug discovery services, helping biotech and pharma partners discover and develop new drugs. The scope of services offer includes high quality services starting from chemistry (computational, medicinal, process chemistry, custom synthesis), through protein biochemistry up to complex in vitro preclinical studies as well as analytics with GMP and GLP certification.
The company has alliances and partnerships with more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe, including R&D partnerships with Merck, H3 Biomedicine, and Nodthera Therapeutics/Epidarex Capital.
The company was established in 2007 and currently employs over 380 scientists, among which 30% are PhDs. Selvita is headquartered in Krakow, Poland, with international offices located in Cambridge, MA and San Francisco Bay Area, in the US, as well as in Cambridge, UK.